<DOC>
	<DOCNO>NCT00570726</DOCNO>
	<brief_summary>This study design evaluate efficacy safety use Ranibizumab , effective vascular endothelial growth factor ( VGEF ) inhibitor , treat patient fail bleb , characterize increase fibrosis vascularization conjuctiva , follow trabeculectomy . Six subject one site enrol study .</brief_summary>
	<brief_title>Treatment Failing Blebs With Ranibizumab</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 40 year Patients Openangle Glaucoma trabeculectomy Patients determine fail bleb presence superficial bleb vascularity IOP increase 3 successive visit without topical medication Patients whose intraocular pressure ( IOP ) goal IOP suture lysis digital compression attempt Pregnancy ( positive pregnancy test ) lactation . Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Current infection inflammation either eye Any abnormality prevent reliable applanation tonometry either eye Other nonglaucomatous disease affect visual field , ( pituitary lesion , demyelinate disease , congenital optic nerve anomaly , prior retinal optic nerve vascular occlusive disease , retinal dystrophy degeneration , diabetes HIV AIDS infection ) Strabismus , nystagmus , monocular patient Prior enrollment study Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>